Chu, PhD, Distinguished Research Professor Emeritus of Pharmaceutical and Biomedical Sciences at the College of Pharmacy, University of Georgia
"This is a major step forward for patients with obstructive sleep apnea." "Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," added Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA
The dose escalation for liraglutide spans about five weeks: 0.6 mg for one week, 1.2 mg for one week, 1.8 mg for one week, 2.4 mg for one week, and then 3.0 mg as the maintenance dose
The physical changes are amazing, but the confidence, energy, and self-love I've gained
Gregory Lubiniecki, vice president of oncology clinical research at Merck Research Laboratories, noted in a statement that prognoses are generally poor for this disease and said the company is pleased to offer a new first-line treatment option. The approval was backed by results from the Phase II/III KEYNOTE-483 trial, where Keytruda elicited a significant survival benefit for patients, cutting the risk of death by 21%